A core, overlooked element of the Biohub's success is physically bringing together scientists and engineers from competing universities like Stanford, UCSF, and Berkeley. This simple act of co-location dismantled institutional barriers and fostered a level of collaboration that was previously uncommon.

Before becoming a biotech hub, Kendall Square's technological and infrastructure foundation was laid by non-biotech companies like Polaroid. This pre-existing industrial base, including old factories and a skilled workforce, provided the initial ingredients that allowed early biotech giants like Genzyme to establish themselves and thrive.

To find power and land quickly, AI infrastructure developers are acquiring sites previously designated for green hydrogen projects. These locations, which already aggregated land, renewable power, and grid connections, can be repackaged for data centers, providing a massive shortcut in development timelines.

Former industrial cities are experiencing a renaissance as potential biotech hubs. They offer a unique combination of established universities, a history of manufacturing, and, crucially, low property and living costs left over from de-industrialization, creating an attractive environment for startups.

IREN strategically builds new data centers where old manufacturing has shut down. These locations possess heavy electrical infrastructure—sunk capital—that can be repurposed. This allows IREN to rehire and retrain local workforces, bringing a new high-tech industry to economically depressed towns.

Cities vying for biotech hub status can experience rapid real estate development that outpaces demand during industry downturns. This leads to high vacancy rates and cheaper lab space, a boon for small biotechs but a risk for developers and a warning for other aspiring cities.

Traditional "flexible" lab design pre-engineers for every possible future scenario, which is expensive and rigid. A smarter approach is "adaptability": consciously designing pathways and leaving space for future technology without over-investing in systems that may quickly become obsolete.

CZI's Biohub model hinges on a simple principle: physically seating biologists and engineers from different institutions (Stanford, UCSF, Berkeley) together. This direct proximity fosters collaboration and creates hybrid experts, overcoming the institutional silos often reinforced by traditional grant-based funding.

The use of low-cost, scalable plastic tank bioreactors eliminates the need for traditional, expensive GMP facilities. This allows companies to convert cheap, underutilized office space into production labs, enabling a novel business model of decentralized, onshore manufacturing that dramatically lowers real estate and operational costs.